Eli Lilly stock gains 2.86 percent as guidance rises

Published on 09/25/2026 at 15:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Eli Lilly stock delivered Q2 2026 adjusted EPS of USD 8.38 versus USD 6.01 consensus. Revenue reached USD 22.97 billion, up 48 percent year over year.

Extreme Makroaufnahme eines hochpolierten Edelstahlflanschs mit O-Ring-Dichtung einer Vakuumkammer auf schwarzem Hintergrund — Lam Research US5324571083 Makro polierter Vakuumkammer Flansch mit O Ring Dichtung auf schwarzem Hintergrund, Illustration mit AI erstellt.

Eli Lilly stock (ISIN US5324571083) rose 2.86 percent to USD 1,183.86 on the NYSE on September 24, 2026 at 8:00 p.m. UTC, compared with a prior close of USD 1,150.99. The move came as the latest quarterly figures and raised revenue outlook continued to shape the investment case.

Q2 revenue jumps 48 percent

For Q2 2026, adjusted earnings per share reached USD 8.38, versus the Zacks consensus estimate of USD 6.01. Revenue rose 48 percent year over year to USD 22.97 billion, exceeding the USD 20.26 billion consensus estimate, according to Zacks in its September 4, 2026 report.

The operating mix also showed a sharp volume effect: reported volumes rose 60 percent, while net realized prices declined 13 percent in Q2 2026. That contrast makes product demand and pricing the central balance for the next earnings cycle.

Guidance points to higher sales

Lilly raised its full-year 2026 revenue guidance to USD 85 billion-USD 87 billion from USD 82 billion-USD 85 billion. At the same time, adjusted EPS guidance narrowed to USD 35.50-USD 36.50 from USD 35.50-USD 37.00, and performance-margin guidance increased to 49.0 percent-50.0 percent from 47.0 percent-48.5 percent, according to Zacks.

Analyst expectations also moved higher in September. Berenberg upgraded Lilly to Buy from Hold and raised its price target to USD 1,400 from USD 1,220 on September 15, 2026, according to MarketScreener. Guggenheim separately maintained a Buy rating and lifted its target to USD 1,284 from USD 1,273 on September 18, 2026, the same outlet reported.

Stock remains below yearly high

The reference quote of USD 1,183.86 was 8.41 percent below the 52-week high of USD 1,292.65 and 66.26 percent above the 52-week low of USD 712.05. Market capitalization stood at USD 1,114,889,500,260, with volume at 2,404,412 shares on September 24, 2026.

Next results arrive October 29

Lilly lists its Q3 2026 earnings call for October 29, 2026 at 10:00 a.m. EDT on its investor-relations page, giving investors a dated checkpoint for the revenue trajectory and the effect of pricing pressure. The company profile identifies Eli Lilly and Company as a healthcare pharmaceutical business, while the Q2 figures show that volume growth remains the stronger quantified driver.